$SPRB
Spruce Biosciences Inc
PRICE
$2.29 ▲1.778%
Extented Hours
VOLUME
70,980
DAY RANGE
2.23 - 2.33
52 WEEK
0.9547 - 3.57
Join Discuss about SPRB with like-minded investors
@soheil.n #StockTraders.NET
looks like will be another quiet day for me...no borrows on any of the gappers: $BVXV, $RELI, $SPRB and $MBOT
47 Replies 10 👍 10 🔥
Key Metrics
Market Cap
89.43 M
Beta
1.65
Avg. Volume
160.02 K
Shares Outstanding
39.75 M
Yield
0%
Public Float
0
Next Earnings Date
Next Dividend Date
Company Information
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess, representing 3-5% of females with PCOS (estimated to be 150,000 to 200,000 patients in the United States).
Website: www.sprucebiosciences.com
HQ: ,
Related News